top of page
US FDA grants Qualified Infectious Disease Product designation to Venus Remedies’ VRP-034, a novel polymyxin B formulation
Developed by Venus Medicine Research Centre (VMRC), the R&D division of Venus Remedies, VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate
Apr 173 min read
bottom of page